

## EVALUATION OF EFFECTIVENESS AND SAFETY OF ELADOCAGENE EXUPARVOVEC IN THE TREATMENT OF AROMATIC L-AMINO ACID DECARBOXYLASE (AADC) DEFICIENCY IN UNIVERSITY HOSPITAL: A CASE REPORT.

<sup>1</sup>L.A.FIORITO, <sup>1</sup>N.PERROTTA, <sup>2</sup>R.POSCIA, R. <sup>1</sup>GENTILE.  
<sup>1</sup>POLICLINICO UMBERTO I, PHARMACY, ROME, ITALY.  
<sup>2</sup>POLICLINICO UMBERTO I, CLINICAL RESEARCH AND CLINICAL COMPETENCE, ROME, ITALY.


### Background and importance

Aromatic L-amino acid decarboxylase deficiency (AADC) is a rare genetic disorder that causes a reduction in neurotransmitter levels, leading to severe motor dysfunction. This case report details the improvement in the clinical condition of the only patient in Italy treated with Eladocagene Exuparvovec, 12 months after intraputamenal infusion.

AADC deficiency is a rare, inherited disorder of neurotransmitter synthesis<sup>1</sup>



AADC deficiency is caused by mutations in the *DDC* gene, of which there are >100 with known pathological variants<sup>2-8</sup>



### Aim and objectives

The objective is to highlight new therapeutic effects, given the paucity of data in the literature with only 26 interventions have been conducted in clinical trials worldwide. This paper presents the case of a three-year-old patient with a confirmed diagnosis of AADC. The patient exhibited the following neurological indications and symptoms upon initial presentation: bradykinesia, oculo palpebral seizures, dystonia, disturbances in sleep patterns, fluctuations in body temperature, hyperhidrosis, hypokinesia, hypotonia, ptosis of the eyelids, and developmental delays. Additionally, he exhibited non-neurological indications, including short stature, nasal congestion, feeding difficulties, recurrent respiratory infections, and poor weight gain.

#### Eladocagene exuparvovec





Image adapted from Hwu P W-L, et al. 2021.<sup>2</sup>

### Material and methods

Eladocagene Exuparvovec has been administered via bilateral infusions at two sites per putamen, comprising four separate infusions(1), during a single surgical session conducted in May 2023. The patient then underwent a one-year follow-up period following the infusion. Surgical interventions in patients with AADC deficiency require collaboration between several specialities within the multidisciplinary team. The treatment was approved by Italian Medicines Agency (authorization no. 120/2023).

### Results

Significant enhancements in motor and cognitive abilities were observed within a 12-month period following the administration of the gene therapy. The patient exhibited a Peabody Developmental Motor Scale, version 2 (PDMS-2) score of 8 after 12 months, representing a four-point improvement from the baseline measurement. Increased de novo dopamine production was demonstrated by PET and neurotransmitter analyses. The patient's symptoms as mood, sweating, temperature and oculogyric crises and quality of life improved.



Adapted from Knierim J. 2020.<sup>2</sup>

Gene therapy is the introduction or change of genetic material, such as DNA, to treat disease<sup>1-3</sup>




Gene therapy for AADC deficiency is aimed at correcting the underlying defect by enabling production of the AADC enzyme, which catalyzes the synthesis of dopamine<sup>4</sup>

- The *DDC* gene, which codes for AADC, is delivered by a recombinant AAV2 vector<sup>5</sup>
- The rAAV2 vector is injected into the putamen by stereotactic surgery<sup>5</sup>



Eladocagene exuparvovec is a targeted strategy for the treatment of AADC deficiency<sup>6</sup>

- It is an rAAV2 vector containing the coding region of the human AADC enzyme<sup>6</sup>
- Infusions are administered bilaterally into the putamen by stereotactic surgery<sup>6</sup>



Intraputamenal gene therapy for the treatment of AADC deficiency has been investigated in Taiwan, Japan, USA and France<sup>5,7-11</sup>



1

Eladocagene exuparvovec will be provided in a single-use vial and administered via bilateral intraputamenal infusion in one surgical session<sup>1</sup>



Eladocagene exuparvovec will be administered at two sites per putamen. Four separate infusions will be performed to the right anterior putamen, right posterior putamen, left anterior putamen and left posterior putamen<sup>1</sup>

### Conclusion and relevance

No brain lesions were detected. No adverse events in treated patient were recorded, although mild and moderate dyskinesia was reported in clinical trials and disappeared within a few months. Therefore, treatment with Eladocagene Exuparvovec in AADC provided durable and significant benefits with an acceptable safety profile.

### References

(1) Upstaza (Eladocagene Exuparvovec) Summary of Product Characteristics. PTC Therapeutics. 2022.

